Susquehanna International Group, LLP Satsuma Pharmaceuticals, Inc. Call Options Transaction History

Susquehanna International Group, LLP

  • $527 Billion
  • Q2 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2023

May 16, 2023
SELL
$0.7 - $1.07 $29,959 - $45,796
-42,800 Reduced 30.4%
98,000 $68,000
Q4 2022

Feb 14, 2023
BUY
$0.61 - $5.06 $71,126 - $589,996
116,600 Added 481.82%
140,800 $126,000
Q3 2022

Nov 14, 2022
BUY
$4.19 - $7.95 $101,398 - $192,390
24,200 New
24,200 $145,000

About Satsuma Pharmaceuticals, Inc.

STSA Quotes by TradingView
  • Ticker STSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,587,500
  • Description
  • Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...
More about STSA
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email